Table 2. Treatment of relapsed/refractory B-cell lymphoma with autologous anti-CD19 CAR T cells.
| No. | Age (years) | Sex | Malignancy | Extranodal involvement (region) | No. of prior therapies | Positive rate of MYC protein expression (%) | A large mass at first diagnosis (major axis >7 cm) | Large mass before infusion of Anti-CD19 CAR T Cells (major axis >7 cm) | Response | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Courses | Lines | No. of rituximab | Type | PFS (days) | OS (days) | ||||||||||
| 30d | 90d | Endpoint | |||||||||||||
| P007 | 65 | Male | DLBCL | Bone marrow, hydrothorax, ascites | 34 | 6 | 22 | 20 | Y | – | CR | CR | D | 142 | 142 |
| P011 | 31 | Male | DLBCL | – | 15 | 5 | 14 | 30 | Y | Y | PR | PR | D | 105 | 253 |
| P014 | 40 | Male | DLBCL | – | 10 | 3 | 0 | 10 | – | – | PR | CR | CR | 1,017 | 1,017 |
| P016 | 29 | Female | DLBCL | Bilateral breast | 16 | 4 | 10 | 10 | – | – | PR | CR | CR | 1,010 | 1,010 |
| P018 | 69 | Male | DLBCL | Crus skin | 16 | 3 | 7 | 80 | Y | Y | PR | PD | D | 54 | 146 |
| P025 | 49 | Male | MCL | Stomach, duodenum, small intestine, colon | 11 | 3 | 1 | – | – | Y | PR | CR | CR | 975 | 975 |
| P032 | 68 | Male | DLBCL | – | 8 | 2 | 0 | 40 | Y | – | PR | PD | D | 45 | 151 |
| P040 | 42 | Female | DLBCL | – | 11 | 4 | 0 | 20 | Y | Y | PR | CR | CR | 876 | 876 |
| P108 | 53 | Male | DLBCL | – | 12 | 2 | 5 | 5 | – | – | PR | CR | CR | 565 | 565 |
| P185 | 49 | Female | DLBCL | Uterus, fallopian tube, ovary, lung, adrenal gland, vagina, thoracic vertebra | 8 | 2 | 3 | 30 | – | – | CR | PD | PD | 109 | 162 |
| P189 | 61 | Male | MCL | – | 13 | 4 | 8 | - | – | – | CR | CR | CR | 130 | 130 |
CAR, chimeric antigen receptor; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; PFS, Progression Free Survival; OS, overall survival; CR, complete remission; PR, partial remission; PD, progression of disease; D, Death of any cause.